October 16: Protecting Innovation at the Intersection of Software and Life Sciences

The importance of software in the health care and pharmaceutical industries is undeniable. And the future will see software-based innovation become an even more essential part of diagnosis and treatment modalities, including new applications for artificial intelligence (AI) and other nascent technologies. However, seemingly few pharmaceutical and medical device companies have adapted to this new reality by developing in-house capabilities to evaluate how to protect these technologies. This webinar will examine issues that in-house counsel need to consider, including:

• IP protection of AI in drug development, personalized medicine, and medical devices.
• Section 101 problems unique to software applications in the Life Sciences area, including the impact of Vanda and Berkheimer.
• Non-patent alternatives to protecting Life Sciences Intellectual Property, including trade secret protection.
• Licensing issues for software in the Life Sciences

Title:
Protecting Innovation at the Intersection of Software and Life Sciences
When/Where:
October 16, 2018 10:00 - 11:15 CENTRAL TIME
Webcast - Register Now!
Speaker:
MBHB attorneys Grantland Drutchas and Aaron Gin, Ph.D.
Cost:
While there is no fee to participate, all attendees must register in advance and, in order to receive MCLE credit, must participate online and individually. Register online here
Credit:
MCLE credit is pending for the states of California, Illinois, New Jersey,* New York,* North Carolina and Virginia (*via reciprocity).
By:
McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.

More Information And Registration